Result of a Cooperative Study with L-Asparaginase in Human Leukemias
Through the Paul-Ehrlich-Society for Chemotherapy, clinical trials of L-asparaginase 1 were conducted in three different programs (Table 1): First, in an orientation trial, an attempt was made to treat all cases of acute leukemias at a constant dose of 200 IU/kg daily intravenously for a period of 4 weeks.
KeywordsComplete Remission Acute Lymphoblastic Leukemia Lymphoblastic Leukemia Acute Leukemia Acute Promyelocytic Leukemia
Unable to display preview. Download preview PDF.